In the last trading session, 3.34 million shares of the Rigel Pharmaceuticals (NASDAQ:RIGL) were traded, and its beta was 1.06. Most recently the company’s share price was $1.13, and it changed around $0.05 or 4.63% from the last close, which brings the market valuation of the company to $198.18M. RIGL currently trades at a discount to its 52-week high of $1.96, offering almost -73.45% off that amount. The share price’s 52-week low was $0.71, which indicates that the current value has risen by an impressive 37.17% since then. We note from Rigel Pharmaceuticals’s average daily trading volume that its 3-month average coming to 1.31 million.
Rigel Pharmaceuticals stock received a consensus recommendation rating of Buy, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended RIGL as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
Instantly RIGL has showed a green trend with a performance of 4.63% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -22.07% year-to-date, but still down -1.74% over the last five days. On the other hand, Rigel Pharmaceuticals (NASDAQ:RIGL) is -22.07% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $1.5, which translates to bulls needing to increase their stock price by 24.67% from its current value. Analyst projections state that RIGL is forecast to be at a low of $1 and a high of $2.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
Rigel Pharmaceuticals share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 23.63 percent over the past six months and at a 64.29% annual growth rate that is well above the industry average of 10.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.96%.
RIGL Dividends
Rigel Pharmaceuticals’s next quarterly earnings report is expected to be released around April 30 and May 06.
